Preview

Bulletin of Siberian Medicine

Advanced search

Interferon status at the women with recurrent genital herpes in combined liposomal RNA treatment

https://doi.org/10.20538/1682-0363-2012-3-166-168

Abstract

The aim of this study was the estimation of the influence of liposomal ribonucleic acid (RNA) medicine «Liprina» on interferon status of women with recurrent genital herpes. In this study 60 women were included, who combined (acyclovir and Liprina, n = 40) or monoterapy with acyclovir (n = 20) were received. The levels of serum interferon alpha and gamma along with cervical virus elimination were estimated. The medicine «Liprina» increased the therapy efficiency of the women with genital herpes, that perhaps related with endogen interferon production amplification.

About the Authors

A. Sh. Makhmutkhodzhayev
Сибирский государственный медицинский университет, г. Томск
Russian Federation


I. D. Yevtushenko
Сибирский государственный медицинский университет, г. Томск


S. N. Targonsky
ЗАО «Вектор-Медика», пос. Кольцово, Новосибирская обл.


C. V. Ussova
ЗАО «Вектор-Медика», пос. Кольцово, Новосибирская обл.


N. M. Dzhilkibayeva
Сибирский государственный медицинский университет, г. Томск


References

1. Аковбян В.А., Масюкова С.А., Владимирова Е.В. и др. Генитальный герпес: современные проблемы и пути их решения // Клинич. микробиология и антимикробная терапия. 2003. Т. 5, № 1. С. 4—18.

2. Исаков В.А., Коваленко А.Л., Романцов М.Г. и др. Модифицированная терапия герпетической инфекции // Клинич. медицина. 2011. № 3. С. 54—57.


Review

For citations:


Makhmutkhodzhayev A.Sh., Yevtushenko I.D., Targonsky S.N., Ussova C.V., Dzhilkibayeva N.M. Interferon status at the women with recurrent genital herpes in combined liposomal RNA treatment. Bulletin of Siberian Medicine. 2012;11(3):166-168. (In Russ.) https://doi.org/10.20538/1682-0363-2012-3-166-168

Views: 5928


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1682-0363 (Print)
ISSN 1819-3684 (Online)